What did @beingmarcellahill actually say?
Marcella Hill describes a constellation of symptoms, including zero sex drive, full-body pain, insomnia, itching, and feeling "completely dead inside," that her OB-GYN dismissed after bloodwork came back "normal." She then found Joy Women's Wellness, a telehealth platform, which sent someone to her home for bloodwork and prescribed testosterone, progesterone, and estrogen. She also mentioned "turdsapatide" (clearly tirzepatide) as a "weight loss peptide" the provider offers.
Her core argument: the conventional medical system fails women with hormone complaints, and telehealth hormone providers fill that gap. That argument is worth taking seriously, but some of what she says is oversimplified or outright incomplete.
Does the science back this up?
On the dismissal piece? Yes, largely. The research on this is not flattering for standard care. Studies have repeatedly shown that perimenopausal and menopausal symptoms are underdiagnosed and undertreated in primary and ob-gyn care settings.
Shifren et al. (2008, Menopause) found that fewer than 25% of women with hypoactive sexual desire disorder ever discussed it with a physician. A 2022 survey published in Menopause (Millheiser et al.) found that many women waited years before receiving a menopause diagnosis. The "your labs look normal" response Hill describes is a documented phenomenon: standard reference ranges for hormones like testosterone and estradiol are often calibrated for reproductive-age women, not perimenopausal ones, and they rarely capture symptoms.
The British Menopause Society and the Menopause Society (formerly NAMS) have both published guidelines emphasizing that symptom assessment, not lab values alone, should drive treatment decisions. Her frustration with the system reflects a real and documented gap in care.
What did they get wrong (or right)?
She got the symptom picture mostly right. Low testosterone, declining estrogen, and progesterone imbalances in perimenopause can collectively produce low libido, joint pain, sleep disruption, and mood changes. The research supports all of those connections (Davis et al., 2015, The Lancet Diabetes and Endocrinology).
Where she gets sloppy: describing tirzepatide as a "weight loss peptide" is reductive and potentially misleading. Tirzepatide (Mounjaro/Zepbound) is a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes and obesity. It is not a simple peptide supplement. Compounded tirzepatide, which telehealth platforms often dispense, is not FDA-approved and is not equivalent to brand-name Zepbound. That distinction matters legally and medically, and she skipped it entirely.
She also implies that Joy Women's Wellness can simply "prescribe you what you need" after a single blood draw. That is an oversimplification. Hormone therapy, particularly testosterone for women, is not FDA-approved for most indications outside of surgically induced menopause, and prescribing it requires ongoing monitoring, not a one-time lab visit.
What should you actually know?
There is a legitimate access problem in women's hormone care, and telehealth platforms have genuinely expanded options for patients who have been dismissed or ignored. That is real. But "outside the regular Healthcare system" is not automatically better. It cuts both ways.
Testosterone therapy for women lacks FDA approval for most indications, though off-label use is supported by some evidence (Islam et al., 2019, The Lancet Diabetes and Endocrinology). That means dosing protocols vary widely across providers, and quality control at compounding pharmacies is inconsistent.
Estrogen and progesterone therapy carry their own risk profiles that depend heavily on personal medical history, including history of hormone-sensitive cancers, clotting disorders, and cardiovascular risk. A monthly vitamin shipment based on bloodwork sounds appealing, but that framing obscures the fact that hormone therapy is a clinical intervention requiring real follow-up, not a wellness subscription.
If your provider dismissed your symptoms, getting a second opinion or seeking a menopause specialist is reasonable. The Menopause Society maintains a directory of certified practitioners. The goal should be informed care, not just easy care.